Akari Therapeutics (AKTX) vs Quantum Biopharma (QNTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Akari Therapeutics (AKTX) has outperformed Quantum Biopharma (QNTM) over the past year, losing 80.1% versus a loss of 81.7%. Over five years, QNTM leads with a -96.6% price change compared with -99.4% for AKTX. Quantum Biopharma is the larger company by market cap ($20.0 million vs $18.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTX | QNTM |
|---|---|---|
| Share price | $8.13 | $3.11 |
| Market cap | $18.58M | $20.00M |
| 1-day change | -5.74% | -1.11% |
| YTD return | -29.67% | -56.92% |
| 1-year return | -80.07% | -81.69% |
| 5-year return | -99.38% | -96.62% |
| EPS (TTM) | $0.00 | $-5.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.00 | $16.36 |
| 52-week low | $3.02 | $2.07 |
| Distance from 52-week high | -79.67% | -80.99% |
| Analyst consensus | none | none |
| Avg. price target upside | +213.65% | +294.53% |
| Average volume | 61.08K | 205.30K |
| Shares outstanding | 2.29M | 6.43M |
| Employees | 5 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Akari Therapeutics
AKTX stock →Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
Healthcare · Biotechnology · 5 employees
About Quantum Biopharma
QNTM stock →Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments.
Healthcare · Biotechnology
AKTX vs QNTM FAQ
Which is bigger, Akari Therapeutics or Quantum Biopharma?
Quantum Biopharma (QNTM) is larger, with a market capitalization of $20.00M compared with $18.58M for Akari Therapeutics (AKTX).
Which stock has performed better over the past year, AKTX or QNTM?
AKTX returned -80.07% over the past 12 months, compared with -81.69% for QNTM (price return, excluding dividends). Past performance does not predict future results.
Are Akari Therapeutics and Quantum Biopharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.